Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS46) (Trehalose free)

产品评论
货号-规格
价格
Qty.
NUN-S46-100ug
¥3990.00
NUN-S46-1mg
¥26250.00
NUN-S46-10mg
¥210000.00
NUN-S46-100mg
¥1680000.00
Fiber-add-1piece
可选服务
询价
合计0件 产品金额¥ 0

产品信息

抗体来源(Source)

Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS46) (NUN-S46) was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant SARS-CoV-2 Nucleocapsid protein. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. As verified by binding test with N-NTD (Cat.No. NUN-C5143) and N-CTD (Cat.No. NUN-C5145) protein, this antibody can only bind to N-NTD (AA Gly 44 - Glu 174).

克隆号(Clone)

AS46

种属(Species)

Mouse

亚型(Isotype)

Mouse IgG1 | Mouse Kappa

偶联(Conjugate)

Unconjugated

种属反应性(Reactivity)

Virus

特异性(Specificity)

This product can recognize SARS-CoV-2 and SARS-CoV Nucleocapsid protein. No cross-reactivity is detected with nucleocapsid protein of other coronaviruses, including MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.

应用(Application)

ApplicationRecommended Usage
ELISA0.2-10 ng/mL

纯度(Purity)

>95% as determined by SDS-PAGE.

纯化(Purification)

Protein A purified / Protein G purified

制剂(Formulation)

Supplied as 0.2 μm filtered solution in PBS, pH7.4.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with blue ice, please inquire the shipping cost.

存储(Storage)

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. For long term storage, the product is stable for up to 3 years at -70°C from date of receipt;
  2. For short term storage, the product is stable for up to 12 months at 2-8°C from date of receipt.

产品数据图

 

电泳(SDS-PAGE)

Nucleocapsid protein SDS-PAGE

Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS46) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Nucleocapsid protein ELISA

Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5227) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (Cat. No. NUN-S46) with a linear range of 0.15-2.5 ng/mL (QC tested).

Protocol

Nucleocapsid protein ELISA

Detection SARS-CoV-2 Nucleocapsid Protein by Sandwich ELISA Assay.
Immobilized Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS46) (Cat. No. NUN-S46) at 4 μg/mL (100 μL/well) can bind SARS-CoV-2 Nucleocapsid Protein (Cat. No. NUN-C5227). And then add Biotinylated Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (Cat. No. NUN-S47L8) at 0.05 µg/mL. Detection was performed using high sensitivity HRP-conjugated streptavidin with sensitivity of 12.5 pg/mL (Routinely tested).

Protocol

Nucleocapsid protein ELISA

Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS46) (Cat. No. NUN-S46) can bind the Delta variant of nucleocapsid protein (Cat. No. NUN-C52Hs).

Protocol

Nucleocapsid protein ELISA

Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS46) (Cat. No. NUN-S46) can bind the Delta variant of nucleocapsid protein (Cat. No. NUN-C52Hp).

Protocol

 

产品评论
发表评论

背景

Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68). The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool.

前沿进展

 
靶点信息
  • 英文全称:

    Nucleocapsid proteins

  • 中文全称:

    核壳蛋白

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    1 详情

  • 最高研发阶段:

    临床一期

数据表和文档
联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品信息
  • 产品数据图
  • 产品评论
  • 背景